Home / Knowledge Centre /

Development of a Pan-Cancer 15 Gene Expression Signature to Detect a Subgroup Driven by MAPK Signalling

Download Almac Diagnostic Services Poster Presentation on ‘Development of a Pan-Cancer 15 Gene Expression Signature to Detect a Subgroup Driven by MAPK Signalling’.

  • A 15 gene signature has been developed from formalin fixed paraffin embedded samples to detect a molecular subgroup driven by MAPK/EMT signalling across multiple diseases .
  • This assay predicts sensitivity to MEK inhibitors in preclinical model systems.
  • Further work aims to validate the EMT assay in clinical samples from patients treated with a MEK or EMT inhibitor.
  • This assay may be helpful for clinical trial enrichment to select patients that are likely to benefit from MAPK or EMT targeted therapies.
View Resource
Almac Logo

Diagnostic Services

Your global partner for biomarker discovery, development & commercialisation.

Genomic Services

We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.

Clinical Trial Assays

Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.

Companion Diagnostics

A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.

Learn More

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies